Managing Director of the Iranian company Mahnaz Qomi said that the registration process for SinaDoxosome is underway in Thailand and Armenia.
Exports to these two countries may start in the next two months, she said.
She went on to say that more than 6,000 vials of SinaDoxosome have been sold inside the country which shows that oncologists' confirmation of its effectiveness.
According to Nanotechnology Products Database, SinaDoxosome is used in the treatment of ovarian cancer, breast cancer, multiple myeloma, and Kaposi sarcoma associated with AIDS; and it is also in clinical trial phase for some other cancers.
In June 2018, Iran Nanotechnology Initiative Council (INIC) announced that nano-medicines, advanced nano-materials and nanotech medical devices are on top list for export.
According to a new market intelligence report by BIS Research, titled 'Global Nanopharmaceutical Drugs Market - Analysis and Forecast, 2018-2026', the global nanopharmaceutical drugs market is anticipated to grow over $79.29 billion by 2026, growing at a compound annual growth rate (CAGR) of 8.12%, during the forecast period from 2018 to 2026. The growth of the market is aided by the remarkable growth in the liposome and polymer drug delivery systems.
Iran has taken wide strides in science and technology, particularly in medical and medicinal fields, in recent years.
On Wednesday, Head of the Food and Drug Administration of Iran Mohammad Reza Shanehsaz announced the export of medicine from Iran in exchange for food imports from various countries, including South American states, have started.
Chairman of the Biotechnology Development Council of Iran Mostafa Qaneyee had also announced on Wednesday that the country produces all raw materials needs for production of biomedicine.
"I declare that we are self-sufficient in production of raw materials for biomedicine and no raw materials are imported to the country in this field," Qaneyee said.
He also underlined plans to produce raw materials for production of chemical drugs, adding, "We are trying to indigenize production of these medicine within 2 to 3 years with the help of Iranian knowledge-based companies."
Qaneyee had announced last year that 17 countries of the world were importing and using the biomedicine products of Iranian scientists.
"Iran enjoys good situation in this field and at present, the biomedicines produced in the country are exported to 17 world states," Qaneyee said last February.
He added that production of biomedicine in Iran saves almost $1bln for the country annually.